§ Yvette Cooper
[holding answer 7 June 2000]The current list of members of the Committee on Safety of Medicines, including interests held in the pharmaceutical industry, was placed in the Library on 9 May. Interests of the members of all Medicines Act Advisory Bodies are published annually in the "Medicines Act 1968 Advisory Bodies—Annual Reports", copies of which are available in the Library. The 1999 report is due to be published in July this year.
Members of the Joint Committee on Vaccination and Immunisation, as at 1 April 2000, who have declared interests in pharmaceutical companies are as follows:Professor Lewis D. Ritchie: Single Company PEPS with Glaxo Wellcome and Zeneca; some industry support to his team for clinical trials work;Dr. Barbara Bannister: Educational sponsorship by SmithKline Beecham to attend CISTM 6th Conference in June 1999; holds portfolio of shares (managed by asset management company) which includes Glaxo Wellcome and SmithKline Beecham; some clinical trial work for new drugs;Dr. David Goldblatt: Occasional member of expert panels for SmithKline Beecham, Wyeth and Pasteur Merieux; research grants to support his team from Wyeth, SKB, Nava and Pasteur Merieux;Professor Roy Anderson: Directorships of Wellcome Trust, Decode, IBHSC; share holdings in Glaxo, Zeneca and SmithKline Beecham;Dr. Karl Nicholson: Has acted as 'consultant' for Glaxo;Professor Keith Cartwright: industry part-funding of his team to evaluate candidate meningococcal vaccines.
The Medicines Control Agency is an executive arm of the Department of Health. There are currently over 500 staff, none of whom have registered links with pharmaceutical companies.